Filing Flows › AbbVie (ABBV) › Guidance & outlook
AbbVie (ABBV) guidance and outlook
AbbVie (ABBV) raised its guidance on Oct 30, 2026: EPS $13.95–$13.99 for FY2026. AbbVie's 10-Q filed Nov 3, 2026 makes 1 forward-looking statements, 0 of them new and 0 no longer said since the filing before.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EPS | FY2026 | $13.95–$13.99 | raised |
From the earnings release filed Oct 30, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- The company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or has the ability to issue additional debt.
AbbVie's latest quarter
AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart follows the revenue to costs, profit and cash.
Questions
Did AbbVie raise or lower its guidance?
AbbVie (ABBV) raised its guidance on Oct 30, 2026: EPS $13.95–$13.99 for FY2026.
What does AbbVie expect?
The company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or has the ability to issue additional debt.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.